Allogene Therapeutics (ALLO) Set to Announce Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) is scheduled to release its earnings data after the market closes on Thursday, November 7th. Analysts expect Allogene Therapeutics to post earnings of ($0.34) per share for the quarter.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Stock Performance

Shares of NASDAQ ALLO opened at $2.60 on Thursday. The stock has a 50 day moving average price of $2.69 and a 200 day moving average price of $2.69. Allogene Therapeutics has a 52 week low of $2.01 and a 52 week high of $5.78. The stock has a market capitalization of $543.69 million, a PE ratio of -1.64 and a beta of 0.83.

Analyst Ratings Changes

ALLO has been the subject of a number of recent analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $14.00 price objective (down from $17.00) on shares of Allogene Therapeutics in a research report on Friday, August 9th. Canaccord Genuity Group cut their price objective on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research report on Wednesday. Oppenheimer initiated coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, Citigroup raised their price objective on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.96.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).